Market research

Companion Animal Health Market 2026

Explore licensesfrom $3,939

Assess the study’s coverageRead the public overview, then compare the chapter outline with your research brief.

28report chapters

Public research overviewHow we research Research team

Companion animal health market context

Companion animal health brings together preventive products, treatments, diagnostics and veterinary services for animals kept as companions. Zoetis's portfolio illustrates the breadth: it includes parasiticides, vaccines, dermatology and pain products, and diagnostics, with offerings for dogs, cats and horses. Veterinarians select and deliver care, while owners weigh the need for care against its cost; suppliers must therefore serve both professional and owner-facing needs.

Commercial models differ by product and jurisdiction. Elanco describes US pet-health sales through veterinary and retail channels, including prescription and over-the-counter products. An authorized product, a listed product and a product that is actually available to a particular buyer are distinct commercial statuses.

Sources and supporting claims 3

360iResearch introduction

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.

  1. Chapter 8 Offering Type

    • Segment Overview
    • Medicinal Products
    • Diagnostic Products
    • Diagnostic Services
    More in this chapter
  2. Chapter 9 Diagnostic Platform

    • Segment Overview
    • Immunoassays
    • Genetic Analysis
    View chapter
  3. Chapter 10 Health Application

    • Segment Overview
    • Parasite Prevention & Control
    • Preventive Care & Health Assessment
    • Infectious Disease Prevention & Management
    More in this chapter

Companion animal health: launches and channel shifts

Commercial competition is moving on two fronts. Elanco reported adding Costco and Dollar General as US parasiticide retail customers in early 2026, while also reporting Credelio Quattro launches in Australia, Canada and Japan by August 2026. The retail additions expand named routes to pet owners; the launches establish company-reported entry, not equivalent clinic coverage in each country.

Product life-cycle changes can also alter competition, but their status matters. On November 5, 2026, the European Medicines Agency's veterinary committee recommended a Credelio variation concerning an additional cat indication. That recommendation was not itself the European Commission's grant of the variation.

Sources and supporting claims 3

AI in companion animal practice commerce

Vetspire offers an AI Scribe that transcribes client conversations and suggests encounter notes for veterinary teams to review. Its documentation says access to encounter AI features depends on the organization's subscription and location settings. This is evidence of a commercial offering, not of market-wide adoption or measured productivity gains.

The business implication is conditional: if documentation tools reduce administrative burden without creating unacceptable review or privacy costs, practices may value them alongside existing software. Suppliers should assess subscription fit, staff review time, data handling and customer acceptance before expanding deployment. Public evidence inspected here does not establish how widely companion-animal practices use these tools or whether AI changes product purchasing.

Sources and supporting claims 2

Regional companion animal health access

North America: Zoetis reported that higher US sales of Simparica Trio, dermatology products and small-animal diagnostics contributed to 2025 companion-animal growth, partly offset by lower Librela sales. This is one supplier's experience, not a regional market total. Latin America: Brazil's agriculture ministry provides registration information for veterinary products; market entry still requires product-specific commercial and distribution evidence.

Europe: EU veterinary medicines may be authorized nationally or EU-wide. That creates a common route for eligible products, but local availability remains a separate question. Middle East: Saudi veterinary guidance distinguishes prescription-only, over-the-counter and controlled supply categories, making product classification relevant to channel choice; the finding should not be extended to the entire region.

Africa: Zoetis South Africa lists dog and cat products including Revolution and Simparica. The listing indicates a local portfolio, not sales across Africa. Asia-Pacific: China registered a feline diagnostic kit in January 2026, while South Korea reported 2025 authorizations that included domestically developed dog heart-disease medicines. These are distinct national regulatory events, not evidence of region-wide adoption.

Sources and supporting claims 7

Companion animal access across geographic groupings

ASEAN: Its 2017 animal-vaccine registration mechanism describes regional coordination with national-authority involvement. Singapore's current requirements also provide a country-specific example of vaccine registration and licensing. The review did not establish how the regional mechanism is implemented across every ASEAN market.

BRICS: Brazil's registration information and China's product-specific registration illustrate separate national evidence; they do not establish a common BRICS authorization or a shared sales channel. European Union: An EU-wide veterinary-medicine authorization route exists alongside national routes, but neither route alone demonstrates that a product is on sale in every member state.

G7: The US channel evidence and Great Britain's national Zenrelia authorization show why portfolio and access planning must remain jurisdiction-specific; they do not characterize every G7 market. GCC: Saudi Arabia's distinction between prescription and over-the-counter veterinary products is relevant to channel selection there, but should not be assumed to apply identically across the GCC. NATO: This review found no companion-animal commercial-access record sufficient to support a NATO-wide market conclusion; national product and channel evidence is needed instead.

Sources and supporting claims 5

Featured companion animal health countries

Australia, Canada and Japan: Elanco reported Credelio Quattro launches in all three by August 2026. The disclosure does not establish comparable local clinic coverage or sales. Brazil: The agriculture ministry provides veterinary-product registration information; product-level registration and channel access remain separate questions. China: The January 2026 feline diagnostic registration is a specific access milestone, not evidence of current sales.

France, Germany, Italy and Spain: Each falls within the EU veterinary-medicine framework, including the possibility of EU-wide authorization. Availability still needs to be established product by product and country by country. India: The national authorization list records Biovet's dog rabies vaccine authorization in 2023; the record does not establish current distribution. Mexico: Zoetis's local dog portfolio lists Simparica and Simparica Trio, but the listing does not establish sales or market share.

Russia: MSD Animal Health's Russian pet portfolio page lists vaccines and antiparasitic categories; current supply and transaction volumes were not established. South Korea: The 2025 authorizations included domestically developed dog heart-disease medicines, but authorization is not proof of commercial uptake. United Kingdom: Great Britain's database records a national Zenrelia authorization for dogs from July 2025; that record is specific to Great Britain. United States: Zoetis reported different 2025 sales movements across companion-animal categories, underscoring the need to assess each product rather than extrapolate from one launch.

Sources and supporting claims 11

Commercial choices for companion animal health leaders

Choose channels by product and jurisdiction. Where a product can be sold through retail, compare the reach of retail partners with the relationships and service support available through veterinary clinics. Elanco's US mix shows both routes are commercially relevant, but it does not establish the economics for another supplier. Favor clinic-led coverage when the product's legal status or buyer-support needs make a retail route unsuitable.

Stage geographic investment. Use authorization and launch records as entry milestones, then look for product-specific availability and repeat demand before committing to broad promotion. EU authorization can support a coordinated strategy, but country availability remains a separate question. A local partnership may be preferable to a direct launch where distribution coverage or counterparty responsibilities are uncertain.

Make the buyer proposition explicit. Assess whether clinics can explain both the offering and its cost to owners. If affordability or service capacity constrains uptake, a narrower portfolio and stronger customer support may be preferable to adding more products. Revisit that choice when observed orders, retention and channel economics justify expansion.

Sources and supporting claims 5

Companion animal health research method

This qualitative review inspected company portfolios and disclosures, veterinary software documentation, and public regulatory records available through November 9, 2026. It compared stated launches, product listings, authorizations and proposed regulatory changes without treating them as equivalent evidence of sales or availability. Native-language official material was inspected for Brazil, China and South Korea.

Coverage is selective rather than a census of providers or countries. Company statements describe their own businesses and may not independently establish market-wide patterns. Group-wide implementation, current local sales, pricing, distribution depth and AI adoption remain incompletely documented. No interviews, surveys, market sizing or experimental research were performed for this report.

Companion animal health outlook

The evidence points to competition across product categories, veterinary relationships and retail access rather than a single uniform global market. Elanco's reported geographic launches and Zoetis's differing US product sales movements illustrate both opportunity and variability.

Useful public milestones to watch include country-specific availability following launches, changes in authorized product indications and repeat channel uptake. In particular, the November 2026 Credelio committee recommendation should be distinguished from any later Commission decision. Commercial success, local supply and the economic impact of veterinary AI remain open questions.

Sources and supporting claims 3

Research report

Table of contents

  1. 1.About This Report
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Scope & Coverage Summary
    4. 1.4Years Considered
    5. 1.5Currency Considered
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Decision Brief
    1. 2.1Headline Numbers
    2. 2.2Key Findings
    3. 2.3Where to Play
    4. 2.4Risks
  3. 3.Executive Summary
    1. 3.1Market Size & Growth Snapshot
    2. 3.2Strategic Implications for Leaders
    3. 3.3Top Revenue Opportunities
    4. 3.4Emerging Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Size & Forecast
    1. 4.1Market Size & Growth
    2. 4.2Growth Contribution by Segment, Region & Country
    3. 4.3Market Outlook
      1. 4.3.1Near-Term Market Outlook (0-2 Years)
      2. 4.3.2Medium-Term Market Outlook (3-5 Years)
      3. 4.3.3Long-Term Market Outlook (5-10 Years)
  5. 5.Market Dynamics
    1. 5.1Growth Drivers
      1. 5.1.1Established wholesale routes can enable professional purchasing
      2. 5.1.2Authorized alternatives can support channel-enabled substitution
    2. 5.2Restraints
      1. 5.2.1Product and professional authorization constrain immediate access
      2. 5.2.2Organized buyers can constrain supplier commercial terms
    3. 5.3Opportunities
      1. 5.3.1Making diagnostic commitments fit the practice
      2. 5.3.2Connecting lawful access with household fulfillment
      3. 5.3.3Defining accountability around therapeutic-device purchases
    4. 5.4Challenges
      1. 5.4.1Establishing current distributor access and commitments
      2. 5.4.2Coordinating retail promotion with supply-policy obligations
      3. 5.4.3Distinguishing a potential alternate from dependable replacement supply
    5. 5.5Impact of Artificial Intelligence
  6. 6.Industry Structure
    1. 6.1Value Chain & Ecosystem
      1. 6.1.1Supply-Side Analysis
      2. 6.1.2Demand-Side Analysis
      3. 6.1.3Stakeholder Analysis
    2. 6.2Porter’s Five Forces
    3. 6.3PESTLE Analysis
    4. 6.4Go-to-Market Strategy
  7. 7.Strategic Insights
    1. 7.1Opportunity Mapping
    2. 7.2Pricing Trends
    3. 7.3Channel Analysis
    4. 7.4Customer Insights
    5. 7.5Customer Experience Benchmarking
    6. 7.6Regulation & Standards
    7. 7.7ESG & Sustainability
    8. 7.8Risk Scenarios
    9. 7.9ROI & Cost-Benefit
  8. 8.Companion Animal Health Market, by Offering Type
    1. 8.1Segment Overview
    2. 8.2Medicinal Products
      1. 8.2.1Pharmaceuticals
      2. 8.2.2Vaccines
    3. 8.3Diagnostic Products
      1. 8.3.1Diagnostic Reagents & Test Kits
      2. 8.3.2Diagnostic Instruments
    4. 8.4Diagnostic Services
    5. 8.5Behavioral Health Products
    6. 8.6Therapeutic Devices
  9. 9.Companion Animal Health Market, by Diagnostic Platform
    1. 9.1Segment Overview
    2. 9.2Immunoassays
    3. 9.3Genetic Analysis
  10. 10.Companion Animal Health Market, by Health Application
    1. 10.1Segment Overview
    2. 10.2Parasite Prevention & Control
    3. 10.3Preventive Care & Health Assessment
    4. 10.4Infectious Disease Prevention & Management
    5. 10.5Dermatologic & Ear Health
    6. 10.6Pain & Mobility Management
    7. 10.7Endocrine & Metabolic Health
    8. 10.8Perioperative & Emergency Care
    9. 10.9Gastrointestinal Health
    10. 10.10Cardiovascular & Respiratory Health
    11. 10.11Renal & Urinary Health
    12. 10.12Behavioral Health
    13. 10.13Oncology
    14. 10.14Oral & Dental Health
    15. 10.15Neurologic Health
    16. 10.16Ophthalmic Health
    17. 10.17Hematologic & Immune Health
    18. 10.18Reproductive Health
  11. 11.Companion Animal Health Market, by Buyer
    1. 11.1Segment Overview
    2. 11.2Pet-owning Households
    3. 11.3Veterinary Healthcare Providers
    4. 11.4Institutional Animal Owners & Caretakers
  12. 12.Companion Animal Health Market, by Administration Route
    1. 12.1Segment Overview
    2. 12.2Oral
    3. 12.3Injectable
    4. 12.4Cutaneous
    5. 12.5Otic
  13. 13.Companion Animal Health Market, by Sales Channel
    1. 13.1Segment Overview
    2. 13.2Veterinary Dispensing
    3. 13.3Supplier Direct Sales
    4. 13.4Wholesale Distribution
    5. 13.5Pharmacy Sales
    6. 13.6Retail Sales
  14. 14.Companion Animal Health Market, by Animal Species
    1. 14.1Segment Overview
    2. 14.2Dogs
    3. 14.3Cats
    4. 14.4Multispecies
    5. 14.5Horses
    6. 14.6Small Mammals
    7. 14.7Birds
  15. 15.Companion Animal Health Market, by Regulatory Access
    1. 15.1Segment Overview
    2. 15.2Prescription Required
    3. 15.3No Prescription Required
  16. 16.Companion Animal Health Market in Asia-Pacific
    1. 16.1Regional Overview
    2. 16.2China
    3. 16.3India
    4. 16.4Japan
    5. 16.5Australia
    6. 16.6South Korea
  17. 17.Companion Animal Health Market in North America
    1. 17.1Regional Overview
    2. 17.2United States
    3. 17.3Canada
    4. 17.4Mexico
  18. 18.Companion Animal Health Market in Latin America
    1. 18.1Regional Overview
    2. 18.2Brazil
  19. 19.Companion Animal Health Market in Europe
    1. 19.1Regional Overview
    2. 19.2United Kingdom
    3. 19.3Germany
    4. 19.4France
    5. 19.5Russia
    6. 19.6Italy
    7. 19.7Spain
  20. 20.Companion Animal Health Market in Middle East
    1. 20.1Regional Overview
  21. 21.Companion Animal Health Market in Africa
    1. 21.1Regional Overview
  22. 22.Competitive Landscape
    1. 22.1Market Share Analysis
    2. 22.2Market Concentration
    3. 22.3Competitive Benchmarking
    4. 22.4Product Portfolio Analysis
    5. 22.5Recent Developments & Impact
  23. 23.Company Profiles
    1. 23.1Zoetis
    2. 23.2Boehringer Ingelheim Animal Health
    3. 23.3Elanco
    4. 23.4IDEXX
    5. 23.5Ceva
    6. 23.6Dechra
    7. 23.7Companion Animal Health
    8. 23.8Pets Drug Mart
    9. 23.9Midwest Veterinary Supply
    10. 23.10DPYP-VET
    11. 23.11SODISAV
    12. 23.12Intas Animal Health
  24. 24.Research Methodology
    1. 24.1Introduction
    2. 24.2Research Design
      1. 24.2.1Primary Research
      2. 24.2.2Secondary Research
    3. 24.3Research Framework
      1. 24.3.1Qualitative Analysis
      2. 24.3.2Quantitative Analysis
    4. 24.4Market Size Estimation
      1. 24.4.1Top-Down Approach
      2. 24.4.2Bottom-Up Approach
    5. 24.5Data Triangulation
    6. 24.6Research Outcomes
    7. 24.7Research Assumptions
    8. 24.8Research Limitations
  25. 25.Segmentation Coverage
  26. 26.Expert Panel
  27. 27.Companies Covered
  28. 28.Economic Groupings
    1. 28.1ASEAN
    2. 28.2GCC
    3. 28.3European Union
    4. 28.4BRICS
    5. 28.5G7
    6. 28.6NATO

Loading the sample request form…